WHAT IS CLAIMED IS:

1. The use of 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide in the manufacture of a medicament for treating non-metastatic castration-resistant prostate cancer in a male human, wherein the medicament is to be used in combination with a gonadotropin-releasing hormone (GnRH) agonist.

2. The use according to claim 1, wherein the non-metastatic castration-resistant prostate cancer is a high risk non-metastatic castration-resistant prostate cancer.

3. The use according to claim 2, wherein the male human with the high risk non-metastatic castration-resistant prostate cancer has a prostate-specific antigen doubling time (PSADT) that is less than or equal to 10 months.

4. The use according to claim 1, wherein administration of the medicament provides an increase in the metastasis-free survival of the male human.

5. The use according to claim 1, wherein the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide is present in the medicament at a dose of about 160 mg.

6. The use according to claim 1, wherein the medicament is for treatment by oral administration of the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide to the male human.

7. The use according to claim 1, wherein the medicament is for treatment by oral administration of the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide on a continuous daily dosing schedule to the male human.

8. The use according to claim 1, wherein the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide is present in the medicament in a unit dosage form, wherein the unit dosage form is in the form of a tablet.

9. The use according to claim 1, wherein the medicament is for administration of the GnRH agonist at a different time as the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide.

10. The use according to claim 1, wherein the medicament is for administration of the GnRH agonist at the same time as the 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-N-methylbenzamide.

11. The use according to claim 1, wherein the male human previously received a first-generation anti-androgen, and wherein the first-generation anti-androgen is bicalutamide, flutamide or nilutamide.

12. The use according to claim 1, wherein the GnRH agonist is leuprolide, buserelin, nafarelin, histrelin, goserelin, or deslorelin.

13. The use according to claim 1, wherein the GnRH agonist is leuprolide.

14. The use according to claim 1, wherein the GnRH agonist is buserelin.

15. The use according to claim 1, wherein the GnRH agonist is nafarelin.

16. The use according to claim 1, wherein the GnRH agonist is histrelin.

17. The use according to claim 1, wherein the GnRH agonist is goserelin.

18. The use according to claim 1, wherein the GnRH agonist is deslorelin.